Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants

The purpose of the study is to evaluate the pharmacokinetics (PK) of suzetrigine (SUZ) and its active metabolite in breast milk of lactating female participants. In addition, the purpose is also to evaluate the relative infant dose (RID), safety and tolerability of SUZ and its active metabolite in lactating female participants.

NCT Number	NCT07378865
Lead Sponsor	Vertex Pharmaceuticals Incorporated
Conditions	Pain
Enrollment	12 participants
Start Date	2026-02-13
Primary Completion	2027-02-26 (estimated)
Study Completion	2027-02-26 (estimated)
Updated on ClinicalTrials.gov	2026-05-13